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Abstract 
Objectives: Cytomegalovirus (CMV) is endemic worldwide, with marked differences in the 
seroprevalence rates between countries. The aim of this study was to analyze the 
seroprevalence of CMV infection in Croatia. 
Methods: During a three year period (2013-2015), 2438 consecutive serum samples collected 
from Croatian residents were tested for the presence of CMV IgM and IgG antibodies using 
enzyme-linked immunoassay. IgM/IgG positive samples were further tested for IgG avidity.  
Results: The overall seroprevalence rates for CMV IgG and IgM antibodies were 74.4% and 
4.3%, respectively. The IgG seroprevalence differed significantly between population groups: 
children/adolescents 54.6%, adult general population 77.2%, hemodialysis patients 91.4% 
(p<0.001). CMV seropositivity was strongly age-dependent with prevalence ranging from 
53.0% in children less than 10 years to 93.8% in persons above 60 years (p<0.001). There was 
no difference in the prevalence between women with normal pregnancy and women with bad 
obstetric history. Gender and place of residence was not associated with CMV seropositivity. 
Using IgG avidity, current/recent primary CMV infection was confirmed by low/borderline 
avidity index (AI) in 46.7% participants, while in 53.3% high AI indicated CMV reactivation 
or reinfection. Primary infections were detected mainly in children and adolescents (83.2% 
and 70.5%), while reactivations/reinfections were common in persons older than 40 (77.0-
100%). Reactivations/reinfections were most commonly detected in hemodialysis patients 
(92.3%). Logistic regression showed that older age and being on hemodialysis were 
significant predictors of CMV seropositivity.  
Conclusions: CMV is widespread in the Croatian population. Older age and being on 
hemodialysis appeared to be main risk factors for CMV infection. 
 
Key words: cytomegalovirus, seroprevalence, Croatia 
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Introduction 
Cytomegalovirus (CMV) is a ubiquitous virus with high worldwide prevalence ranging from 
34%-80% in developed countries to 100% in some parts of Africa [1,2]. Virus is transmitted 
by close personal contacts through infected body fluids, usually saliva, urine, blood or genital 
secretions [3]. Primary CMV infections occur mainly in early childhood or adolescence and 
are usually asymptomatic in otherwise healthy children and adults. Symptomatic CMV 
infections are typically manifested as a non-specific febrile disease or a mild self-limiting 
mononucleosis-like syndrome [4]. However, there are many reports of severe or prolonged 
symptomatic CMV infection in immunocompetent patients [5-7]. After primary infection, 
CMV establishes a lifelong latent infection that can periodically reactivate [3]. 
Immunocompromised individuals such as HIV-infected patients, hemodialysis patients and 
transplant recipients may develop severe CMV disease with a wide spectrum of clinical 
symptoms including retinitis, hepatitis, colitis, pancreatitis, pneumonitis and encephalitis [8-
10]. In addition, pregnant women also represent a risk-group for CMV infection. In 
seronegative pregnant women, CMV transmission can occur following primary maternal 
CMV infection. In seropositive women, CMV can cross the placenta during non-primary 
maternal infection (reactivation of virus or re-infection with a different strain) resulting in 
congenital CMV infection [11]. 
In Europe, there is wide range of CMV seroprevalence among countries and different 
population groups. Prevalence rates are reported to be 41%-92% in children and adolescents 
[12-15], 45%-94% in adult general population [14, 16-19], 30%-91.5% in pregnant women 
[20-24] and 68%-99% in hemodialysis patients [25-27]. 
In Croatia, there are few published studies on the prevalence of CMV infection in selected 
population groups such as childbearing-aged women and hemodialysis patients [28,29]. The 
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aim of this study was to analyze the prevalence of CMV infection in the Croatian general 
population.   
 
Materials and methods 
During a three-year period (January 2013-December 2015), a total of 2438 consecutive serum 
samples were tested for the presence of CMV specific IgM and IgG antibodies. Samples were 
collected from patients residing all Croatian counties testing at two large medical institutions 
(Croatian National Institute of Public Health and Clinical Hospital Center Zagreb). There 
were 1064 males (43.6%) and 1374 females (56.4%) aged one month to 82 years (Figure 1). 
Patients enrolled in the study were admitted to a routine testing for a preoperative check-up 
(cardiac surgery, renal transplant program), elevated liver transaminases, lymphatic disorders, 
neurological disorders, antenatal and postnatal screening, and patients from infertility centers 
(couples undergoing medically assisted reproduction). Among pregnant women, 238 (76.5%) 
had a normal pregnancy and 73 (23.5%) had a bad obstetric history (history of intrauterine 
fetal death, intrauterine growth retardation, stillbirth, and habitual abortions). 
Anti-CMV IgM and IgG antibodies were detected using a commercial enzyme-linked 
immunosorbent assay (ELISA; Vircell, Granada, Spain) and enzyme-linked fluorescent assay 
(ELFA, Vidas, Biomerieux, Marcy l'Etoile, France). Results were interpreted according to the 
manufacturer’s recommendations: Vircell CMV IgM/IgG, antibody index <9 negative, 9-11 
equivocal, >11 positive; Vidas CMV IgM <0.70 negative, 0.70-0.90 equivocal, >0.90 
positive, CMV IgG <4 aU/ml negative, 4-6 aU/ml equivocal, >6 aU/ml positive. IgM/IgG 
positive samples were further tested for IgG avidity to confirm or to rule out primary CMV 
infection using ELISA (Euroimmun, Lübeck, Germany) or ELFA (Vidas, Biomerieux, Marcy 
l'Etoile, France).  
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Statistical analysis 
The frequencies are shown with 95% confidence intervals (CI). Difference between groups 
was assessed using Fischer' exact test. The strength of association between dependent and 
independent variables was assessed using logistic regression (crude odds ratios; OR, odds 
ratios adjusted for age and gender; AOR). Due to mother-to-child passive immunity, the 
youngest age group (<6 months), was excluded from logistic regression models. For statistical 
analysis, software package STATA/IC ver 11.2 (StataCorp LP, USA) was used. The level of 
statistical significance was α= 0.05. 
 
Results 
CMV IgM/IgG seroprevalence according to the characteristics of participant’s is presented in 
Table 1. CMV IgG antibodies were detected in 1815 (74.4%) participants. Women were more 
often seropositive than men (76.3% vs. 72.0%, p=0.015). Of children aged less than 6 months, 
84.4% were IgG seropositive indicating transplacentally derived maternal antibodies. A 
significant progressive increase in IgG seroprevalence with age was observed from 53.0% in 
children aged 6 months to 9 years to 93.8% in persons older than 60 years (p<0.001). There 
was no difference in the CMV prevalence among participants residing urban regions (74.4%) 
and participants residing suburban/rural regions (74.3%, p=0.952). According to population 
group, seropositivity was lowest in children and adolescents (54.6%) compared to adult 
general population (77.2%) and hemodialysis patients (91.4%, p<0.001). In pregnant women, 
there was no difference in the prevalence in women with normal pregnancy and bad obstetric 
history (78.2% vs. 78.1%, p=0.999). Univariate logistic regression showed a steady increase 
in the strength of association between belonging to an older age group and CMV IgG 
seropositivity (ORs 2.03-13.3). In addition, adult general population and hemodialysis 
patients had higher risk for being CMV IgG seropositive compared to children and 
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adolescents (OR 2.82; 95%CI=2.28-3.48 and 8.83; 95%CI=5.73-13.60, respectively). After 
standardization for age and gender, being on hemodialysis remained the main predictor of 
CMV IgG seropositivity (AOR=0.95, 95%CI=1.15-3.41) (Table 2). 
CMV IgM antibodies were documented in 105 (4.3%) participants. IgG avidity was low in 38 
(36.2%) and borderline in 11 (10.5%) participants indicating current/recent primary CMV 
infection. In 56 (53.3%) participants, high IgG avidity was found suggesting CMV 
reactivation or reinfection. Acute infections were most frequently detected in participants 
aged 6 months-9 years (7.6%) and 20-29 years (6.7%), however they occurred in all age 
groups (2.4%-4.3%, p=0.005) (table 1). Avidity indices (AI) according to age groups are 
presented in the Figure 2. Acute primary infections (low AI) were reported mainly in persons 
younger than 30 years (83.2% aged 6 months-9 years, 75.0% aged 10-19 years, 50.0% aged 
20-29 years). In contrast, majority of CMV reactivations/reinfections (high AI) were detected 
in persons above 40 (76.9%-100%). According to the population group, acute infections were 
most common in hemodialysis patients (8.6%) compared to 5.0% in children/adolescents and 
3.3% in adult general population (p<0.001). Among CMV IgM positive hemodialysis 
patients, 92.3% showed high AI indicating reactivation or reinfection. In children/adolescents 
and adult population, prevalence of current/recent primary infection was 80.0%/8.0% and 
33.3%/13.0%, respectively (Figure 3). 
 
Discussion 
The results of this first large seroprevalence study have demonstrated a high seroprevalence of 
CMV infection the Croatian general population (74.4%) with significant differences among 
population groups. Data from European countries showed wide geographical variability. In 
the general population, seroprevalence in Croatia is comparable to that of Portugal (77%) 
[14]. Lower prevalence rates were reported in the Netherlands (45.6%) [19], France (49.5%) 
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[18], Germany (57.25%) [17] and Spain (62.8%) [30], while Hungary, Turkey and Russia 
showed higher seroprevalence rates (86% and 80.9-94.8%, respectively) [10,13,15,16].  
Several European studies have reported a higher CMV seroprevalence in females, although in 
most instances these differences were small [19,30,31].
 
Results of this study revealed similar 
results (76.3% in females vs. 72.0% in males). No gender-specific differences were 
recognized in German adolescents aged 13-16 years [32]. 
CMV seroprevalence in the Croatian population tends to increase progressively with age from 
53.0% in 6 months-9-year-olds to 93.0% in participants older than 60. The only exception to 
this trend was observed in children less than 6 months who had high prevalence (84.4%) 
reflecting transient presence of transplacentally derived maternal IgG antibodies. Similar 
results were found in majority other studies [10,15,18,19,33]. Comparing seroprevalence in 
the similar age groups, some differences were found in children and adolescents. For 
example, in Portugal the overall seroprevalence rate (77%) is similar to that of Croatia 
(74.4%), however, seroprevalence in children/adolescents was higher than in the similar 
population group in Croatia (64.9%-71.3.5% vs. 53.0-55.4%) [14]. Moreover, 82.1% Turkish 
children were infected with CMV by the age of 6 and 92% by the age of 13 [13].  
Several studies published in 1990s-2000s reported higher CMV seroprevalence in 
hemodialysis patients ranging from 83% to 99.3% [25,26,34]. Croatian hemodialysis patients 
showed significantly higher seroprevalence rate (91.4%) than adult general population as well 
(77.2%). In contrast, a Dutch study found the percentage of CMV-seropositive hemodialysis 
patients within range of the reported prevalence in the general population [27]. Higher 
prevalence in hemodialysis patients could be explained by the acquisition of CMV through 
repeated blood transfusions as well as exposure to CMV through contaminated equipment 
during hemodialysis procedures.  
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Studies on the prevalence of CMV in childbearing-aged, pregnant and parturient women 
showed seroprevalence rates of 42.3% in Germany [32], 49% in the United Kingdom [35],
 
56.3% in Finland [36], 57% in France [22], 62.4% in Poland [37] and 91.5%-97.3% in Turkey 
[24,38]. Regional differences in CMV seropositivity were observed in Norway (58.5%-
72.1%) [23,39] and Belgium (30%-54%) [21,31]. A very low prevalence rate was found in 
Irish pregnant women (30.4%) [40]. A Russian study reported slightly higher seroprevalence 
in women with current abortions (81.1%) compared to women with normal pregnancy 
(78.0%) [20]. There was no difference in CMV seropositivity in Croatian pregnant women 
with normal pregnancy (78.2%) and pregnant women with bad obstetric history (78.1%). 
Place of residence was not found to be a risk factor for CMV seropositivity in Croatia which 
is consistent with results from Finland [36] and Turkey [13]. 
In this study, IgM antibodies were detected in 4.3% participants indicating acute CMV 
infection. Since IgM antibodies could be false positive in some population groups such as 
hemodialysis patients and pregnant women, serology results should be interpreted with 
caution. Distribution of acute CMV infections in the Croatian population was bimodal. The 
highest prevalence of acute infections was reported in children between 6 months and 9 years 
(7.6%) and young adults between 20 and 29 years (6.7%). A high prevalence documented in 
young children is probably due to starting attending day-care centers. A study from Belgium 
demonstrated that probability of CMV seroconversion is significantly associated with the 
contact with children aged less than 3 years [31]. In addition to contact with young children, a 
higher prevalence in young adults could be attributable to sexual CMV transmission. 
According to population group, acute infections were common in hemodialysis patients 
(8.6%). Using IgG avidity, recent primary infection (borderline AI) was documented in only 
7.7% patients, while in 92.3% high AI indicated CMV reactivation or reinfection. 
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In conclusion, the results of this study indicate that CMV is widespread in Croatia. More than 
half of the population (54.6%) is infected by age of 20. Older age and being on hemodialysis 
appeared to be main risk factors for CMV infection. 
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Table 1. Prevalence of CMV antibodies according to the participant’s characteristics 
Characteristic Tested 
N (%) 
CMV IgM 
N (%) 
 
95%CI 
 
p 
CMV IgG 
N (%) 
 
95%CI 
 
p 
Overall 2438 (100) 105 (4.3)   1815 (74.4) 72.7 - 76.2  
Gender    0.07   0.015 
     Male 1064 (43.6) 55 (5.2) 3.9 - 6.7  766 (72.0) 69.2 - 74.7  
     Female 1374 (56.4) 50 (3.6) 2.7 - 4.8  1049 (76.3) 74.0 - 78.6  
Age     0.005   <0.001 
     < 6 mo 32 (1.3%) 1 (3.1) 0.1 - 16.2  27 (84.4) 67.2 - 94.7  
     6 mo - 9 yrs 249 (10.2) 19 (7.6) 4.7 - 11.7  132 (53.0) 46.4 - 59.3  
     10 - 19 yrs 271 (11.1) 7 (2.6) 1.0 - 5.2  150 (55.4) 49.2 - 61.4  
     20 - 29 yrs 431 (17.7) 29 (6.7) 4.6 - 9.5  300 (69.6) 65.0 - 73.9  
     30 - 39 yrs 584 (24.0) 14 (2.4) 1.3 - 4.0  420 (71.9) 68.1 - 75.5  
     40 - 49 yrs 278 (11.4) 12 (4.3) 2.3 - 7.4  237 (85.3) 80.5 - 89.2  
     50 - 59 yrs 305 (12.5) 13 (4.3) 2.3 - 7.2  279 (91.5) 87.8 - 94.4  
     60+ yrs 288 (11.8) 10 (3.5) 1.7 - 6.3  270 (93.8) 90.3 - 96.3  
15 
 
Setting    0.604   0.952 
     Urban 1991 (81.8) 83 (4.2) 3.3 - 5.1  1482 (74.4) 72.5 - 76.3  
     Suburban/rural 444 (18.2) 21 (4.7) 3.0 - 7.1  330 (74.3) 70.0 - 78.3  
Population group    <0.001   <0.001 
     Children/adolescents 496 (20.4) 25 (5.0) 3.3 - 7.4  271 (54.6) 50.1 - 59.1  
     Adult general population 1626 (66.7) 53 (3.3) 2.5 - 4.2  1256 (77.2) 75.1 - 79.3  
     Hemodialysis patients 314 (12.9) 27 (8.6) 5.7 - 12.3  287 (91.4) 87.7 - 94.2  
Pregnant women    0.999   0.999 
     Normal pregnancy 238 (76.5) 2 (0.8) 0.1 - 3.0  186 (78.2) 72.4 - 83.2  
     Bad obstetric history 73 (23.5) 0 (0) 0 - 4.9  57 (78.1) 66.9 - 86.9  
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Table 2. Univariate logistic regression for risk of CMV seropositivity 
Characteristic CMV IgM 
OR 
95%CI OR CMV IgM 
AOR* 
95%CI AOR CMV IgG 
OR 
95%CI OR CMV IgG 
AOR 
95%CI AOR 
Male vs. female (ref.) 1.44 0.98 - 2.14 NA** NA 0.80 0.66 - 0.96 NA NA 
Age    NA NA   NA NA 
     6 mo - 9 yrs 1 (ref.) -   1 (ref.) -   
     10 - 19 yrs 0.32 0.13 - 0.78   1.10 0.78 - 1.55   
     20 - 29 yrs 0.87 0.48 - 1.59   2.03 1.47 - 2.80   
     30 - 39 yrs 0.30 0.15 - 0.60   2.27 1.67 - 3.09   
     40 - 49 yrs 0.55 0.26 - 1.15   5.12 3.38 - 7.76   
     50 - 59 yrs 0.54 0.26 - 1.11   9.51 5.93 - 15.26   
     60 + yrs 0.44 0.20 - 0.96   13.30 7.76 - 22.77   
Urban vs. suburban/rural 
setting (ref.) 
0.88 0.54 - 1.43 0.89 0.55 - 1.46 1.01 0.79 - 1.27 0.94 0.73 - 1-20 
Population group         
     Children/adolescents  1 (ref.) - 1 (ref.) - 1 (ref.) - 1 (ref.) - 
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     Adult general population 0.63 0.39 - 1.03 1.57 0.81 - 3.06 2.82 2.28 - 3.48 0.94 0.69 - 1.29 
     Hemodialysis patients 1.77 1.01 - 3.11 6.16 2.57 - 14.75 8.83 5.73 - 13.60 1.98 1.15 - 3.41 
Bad obstetric history vs. 
normal pregnancy (ref.)  
NA - NA - 1.00 0.53 - 1.88 0.95 0.50 - 1.81 
*AOR=adjusted for age and gender; **NA=not applicable 
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FIGURE LEGENDS: 
Figure 1. Distribution of study participants according to age and gender 
 
Figure 2. CMV IgG avidity according to participant’s age 
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Figure 3. CMV IgG avidity according to population group 
 
